Source comparison
CJC-1295 No DAC & Ipamorelin Bioavailability: Comparison
The table below compares absorption kinetics, stability requirements, and administration considerations for CJC-1295 no DAC and ipamorelin when used in research protocols. Molecular Weight ~3,367 Da 711 Da Smaller peptides diffuse faster across capillary membr
This comparison does not assign a generated winner or score.
- The table below compares absorption kinetics, stability requirements, and administration considerations for CJC-1295 no DAC and ipamorelin when used in research protocols.
- Molecular Weight
- ~3,367 Da
- 711 Da
- Smaller peptides diffuse faster across capillary membranes—ipamorelin reaches systemic circulation more rapidly
- Subcutaneous Bioavailability
- 90–95% (when stored correctly)
- 85–90% (when stored correctly)
- Both bypass hepatic first-pass metabolism; oral administration yields near-zero absorption due to gastric protease degradation
- Time to Peak Plasma Concentration (Tmax)
- 30–45 minutes post-injection
- 20–30 minutes post-injection
- Ipamorelin's smaller size results in faster absorption kinetics; dosing timing must account for this difference
- Plasma Half-Life
- ~30 minutes
- ~2 hours
- CJC-1295 no DAC requires more frequent dosing or stacking with longer-acting analogs to maintain pulsatile GH release
- Storage Temperature (Reconstituted)
- 2–8°C; use within 28 days
- Temperature excursions above 8°C for >48 hours cause irreversible denaturation—bioavailability collapses to near-zero
- Reconstitution Medium
- Bacteriostatic water (0.9% benzyl alcohol)
- Sterile water lacks preservative—bacterial growth degrades peptides within days; saline can shift pH and denature structure
- Professional Assessment
- Fast-acting GHRH analog; requires precise reconstitution and cold-chain maintenance to preserve bioavailability
- Ghrelin mimetic with longer half-life; slightly more forgiving kinetics but same storage/reconstitution requirements
- Both peptides fail at the preparation stage far more often than at the injection stage—protocol adherence determines therapeutic outcome